These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18452854)

  • 1. Adverse events of unapproved drugs in Japan.
    Miyakoshi S; Kusumi E; Kodama Y; Narimatsu H; Hamaki T; Matsumura T; Kami M
    Lancet Oncol; 2008 May; 9(5):414-5. PubMed ID: 18452854
    [No Abstract]   [Full Text] [Related]  

  • 2. Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.
    Narimatsu H; Hori A; Matsumura T; Kodama Y; Takita M; Kishi Y; Hamaki T; Yuji K; Tanaka Y; Komatsu T; Kami M
    J Clin Oncol; 2008 Dec; 26(35):5820-3. PubMed ID: 19001340
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhancing care and managing side effects in patients receiving bortezomib.
    Colson K
    Clin Adv Hematol Oncol; 2006 May; 4(5):6-7; discussion 8; suppl 13. PubMed ID: 16832860
    [No Abstract]   [Full Text] [Related]  

  • 4. Subcutaneous bortezomib: a step towards optimised drug use.
    Mateos MV
    Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
    [No Abstract]   [Full Text] [Related]  

  • 5. Speedy approvals for new cancer treatments.
    FDA Consum; 2003; 37(4):36. PubMed ID: 12971348
    [No Abstract]   [Full Text] [Related]  

  • 6. Children are not large mice.
    Horton T; Hunger SP
    Eur J Haematol; 2013 Jun; 90(6):535. PubMed ID: 23534840
    [No Abstract]   [Full Text] [Related]  

  • 7. Bortezomib.
    Tariman JD; Lemoine C
    Clin J Oncol Nurs; 2003; 7(6):687-9. PubMed ID: 14705489
    [No Abstract]   [Full Text] [Related]  

  • 8. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lung injury associated with bortezomib therapy in Japan].
    Mukai H; Ohyashiki K; Katoh T; Kusumoto M; Gemma A; Sakai H; Sugiyama Y; Hatake K; Fukuda Y; Kudoh S
    Rinsho Ketsueki; 2011 Dec; 52(12):1859-69. PubMed ID: 22241153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib.
    Paramore A; Frantz S
    Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
    [No Abstract]   [Full Text] [Related]  

  • 12. Bortezomib-induced cutaneous lupus in a patient with myeloma.
    Heelan K; McKenna DB
    J Dermatol; 2013 Feb; 40(2):123-4. PubMed ID: 23078265
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
    Duek A; Feldberg E; Haran M; Berrebi A
    Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of novel therapeutics' side effects: a nurse-centric model.
    Davies MJ
    ONS Connect; 2007; 22(8 Suppl):25-6. PubMed ID: 17824551
    [No Abstract]   [Full Text] [Related]  

  • 15. Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases.
    Truchuelo M; Bagazgoitia L; Alcántara J; Velasco D; Carrillo R
    Actas Dermosifiliogr; 2012 Nov; 103(9):829-31. PubMed ID: 22652505
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.
    Wright J; Hillsamer VL; Gore-Langton RE; Cheson BD
    Oncology (Williston Park); 2000 Nov; 14(11):1589-90, 1593-4, 1597. PubMed ID: 11125942
    [No Abstract]   [Full Text] [Related]  

  • 17. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
    Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib-induced lupus erythematosus tumidus.
    Böckle BC; Baltaci M; Weyrer W; Sepp NT
    Oncologist; 2009 Jun; 14(6):637-9. PubMed ID: 19474161
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib-associated cutaneous vasculitis.
    Garcia-Navarro X; Puig L; Fernández-Figueras MT; Dalmau J; Roe E; Alomar A
    Br J Dermatol; 2007 Oct; 157(4):799-801. PubMed ID: 17635511
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib (velcade) for multiple myeloma.
    Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.